Nuri Braintech

Company Overview

Snapshot

Founded in July 2024 by Dan Rappaport and Miri Polachek, Nuri Braintech operates with 1-10 employees. The company has secured funding across two rounds. In April 2025, Nuri Braintech raised a Pre-Seed round led by embARC Ventures.

Business overview

Nuri Braintech is developing an implantable brain-computer interface (BCI) designed to modulate emotions for individuals with severe, treatment-resistant psychiatric conditions. Their core technology detects, decodes, and recalibrates dysfunctional emotional circuits through real-time, closed-loop neuromodulation via Deep Brain Recoding (DBR). The company aims to personalize treatment protocols based on each patient’s neural signature, initially targeting PTSD and planning expansion across other psychiatric indications. Nuri Braintech operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.

Company Intelligence Q&A

What is Nuri Braintech's core technology?

Nuri Braintech has developed the first emotion brain-computer interface (eBCI) for psychiatry that detects, decodes, and recalibrates trauma responses at their source through real-time, closed-loop neuromodulation via Deep Brain Recoding (DBR).

When was Nuri Braintech founded and by whom?

Nuri Braintech was founded in July 2024 by Dan Rappaport and Miri Polachek.

Which investor led Nuri Braintech's Pre-Seed funding round?

In April 2025, Nuri Braintech raised a Pre-Seed funding round led by embARC Ventures.

Has Nuri Braintech received any non-equity funding?

In July 2025, Nuri Braintech secured a grant from the Israel Innovation Authority.

What is Nuri Braintech's primary focus for treatment?

Nuri Braintech aims to transform care for people with severe, treatment-resistant psychiatric conditions, beginning with PTSD and expanding across other psychiatric indications, by modulating emotional patterns.